Seeing the Field

Guest content from Sandy Graham, managing partner at Sequoyah Associates: Can you “see the field” of opportunity? Have your clearly defined your plan to achieve your entrepreneurial dreams? Have you mapped out the strategic direction to attain your plan? Have you envisioned your market and know how to position your business to acquire it? Do […]


Promote your expertise

Did you know that BiotechBlog posts are syndicated to outlets such as Reuters, Biospace, San Francisco Gate, Chicago Sun-Times, and dozens of other media outlets? BiotechBlog provides a forum to promote your expertise through the publication of actionable industry guidance. See guest content and the submission guidelines for more information


Call for papers: Biotechnology Investing

The Journal of Commercial Biotechnology is looking for papers on investing strategies in the biotechnology space. The scope can include valuation models, strategies to identify under-valued companies, case studies in developing and managing a portfolio, etc. The Journal of Commercial Biotechnology is a peer-reviewed journal focused on the business of biotechnology. More information, instructions for […]


BIO2008 book signing

For those attending BIO2008 in San Diego this year, I’ll be doing a signing of my books on Wednesday June 18th from 10-11. There will also be a limited number of free copies of the Journal of Commercial Biotechnology, so be sure and show up early! I’ll also be speaking on Friday morning: Title: Scientific […]


Seeking reviewers and contributors for next edition of Building Biotechnology

I’ve nearly completed revisions for the third edition of Building Biotechnology, the leading textbook on the business of biotechnology. This new edition has several new chapters, new case studies, updated case law, and fresh industry stats — more than 100 pages longer than the second edition. I’m looking for volunteers to review the chapters and […]


Dyadic founder fights to regain control of company

The science of biotechnology is tough. R&D can be unpredictable, and most products need regulatory approval before they can be sold. But biotechnology companies also need to worry about other problems, like management issues. The case of Dyadic’s illustrates some of the often-overlooked challenges in commercializing biotechnology. Mark Emalfarb founded Dyadic in 1979 as a […]


Drug Patent Expirations in May 2008

Courtesy of DrugPatentWatch.com: Drug Patent Expirations in May 2008 *Drugs may be covered by multiple patents Tradename Applicant Generic Name Patent Number Patent Expiration HABITROL Novartis nicotine 5,016,652 May 21, 2008 REQUIP Glaxosmithkline ropinirole hydrochloride 4,824,860 May 19, 2008 SARAFEM Lilly fluoxetine hydrochloride 4,971,998 May 20, 2008 Courtesy of DrugPatentWatch.com


Why so quiet?

Apologies for light posting as of late. I’ve been buried deep in revisions to Building Biotechnology and prepping for an upcoming talk. Writing is coming to a close, so soon I’ll be looking for external reviewers and case study contributions. For those of you attending BIO 2008, I’ll be presenting in a session on trends […]


Journal of Commercial Biotechnology — March 2008

The March 2008 issue of the Journal of Commercial Biotechnology is now available. The links below will take you to the abstract of each article: Volume 14, Issue 2 Editorial Editorial PDF Yali Friedman Articles Export compliance for life sciences PDF John Avellanet A new approach to improve technology commercialisation in university medical schools PDF […]


Drug Patent Expirations in April 2008

Courtesy of DrugPatentWatch.com: Drug Patent Expirations in April 2008 *Drugs may be covered by multiple patents Tradename Applicant Generic Name Patent Number Patent Expiration ACTINEX Univ Az Cancer Ctr masoprocol 4,695,590 APR 17,2008 ACTINEX Univ Az Cancer Ctr masoprocol 5,008,294 APR 15,2008 ESTROSTEP 21 Warner Chilcott ethinyl estradiol; norethindrone acetate 5,010,070 APR 23,2008 ESTROSTEP FE […]


Do NOT follow this link or you will be banned from the site!